Analysis: The Vikings' improvement meant trouble for the Bears but without an offense Chicago's spot at the bottom of the division seems cemented for now.
Shares in Novo Nordisk (NYSE: NVO) fell more than 4% following the market open on Friday after the Danish pharma giant released data from a phase 2a clinical trial with its obesity drug, monlunabant.
Some results have been hidden because they may be inaccessible to you